Gyre TherapeuticsGYRE -1.37%39 Days Inventory is 800.32 as of Mar. 2026, which is 60% above its 10-year median of 498.91. GuruFocus rates GYRE with a GF Score™ of 39/100 and a GF Value™ of $9.82 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 638 Biotechnology companies, Gyre Therapeutics ranks worse than 84.17% on this metric.
The historical rank and industry rank for Gyre Therapeutics's Days Inventory or its related term are showing as below:
GYRE'
s Days Inventory Range Over the Past 10 Years
Min: 409.52 Med: 498.91 Max: 598.27
Current: 598.27
During the past 5 years, Gyre Therapeutics's highest Days Inventory was 598.27. The lowest was 409.52. And the median was 498.91.
GYRE's Days Inventory is ranked worse than 84.17% of 638
companies
in the Biotechnology industry
Industry Median: 183.875
vs GYRE: 598.27
Gyre Therapeutics's Days Inventory
increased
from Mar. 2025 (725.46) to Mar. 2026 (800.32).
It might indicate that Gyre Therapeutics's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Gyre Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.11.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Gyre Therapeutics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.48.
Gyre Therapeutics (NAS:GYRE) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Gyre Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Gyre Therapeutics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Gyre Therapeutics Days Inventory Related Terms
Gyre Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Gyre Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GYRE vs RLMD, ACRS, SGP: Days Inventory Comparison
For the Biotechnology subindustry, Gyre Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics (GYRE) has a Days Inventory of 800.32 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Gyre Therapeutics and its competitors. This is 60% above median its historical median of 498.91. Over the past decade, Gyre Therapeutics' Days Inventory has ranged from 409.52 to 598.27. According to the industry distribution chart, Gyre Therapeutics ranks #537 out of 638 companies in the Biotechnology industry, placing it in the top 84.2%.
Is Gyre Therapeutics' Days Inventory too high?
Gyre Therapeutics' current Days Inventory of 800.32 is 60% above median its 10-year median of 498.91. Over the past 10 years, this metric has ranged from a low of 409.52 to a high of 598.27. The Biotechnology industry median Days Inventory is 183.88. Gyre Therapeutics' value of 800.32 is 335.3% above this industry median. Based on the distribution chart, Gyre Therapeutics ranks #537 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Days Inventory compare to RLMD and ACRS?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #537 out of 638 companies for Days Inventory. This places Gyre Therapeutics in the lower half of its industry. The industry median Days Inventory is 183.88. Gyre Therapeutics' value of 800.32 is 335.3% above this benchmark. Historically, Gyre Therapeutics' own Days Inventory has ranged from 409.52 to 598.27 over the past decade. While the company's 10-year median is 498.91 vs. the industry median of 183.88, Gyre Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gyre Therapeutics's current Days Inventory of 800.32 is 335.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Gyre Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gyre Therapeutics's current Days Inventory is 800.32, which is 60% above median its own 10-year median of 498.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.82, compared to a current price of $6.50 — trading 33.8% below its estimated fair value. The current Days Inventory is 800.32, which is 60% above median its 10-year median of 498.91 and 335.3% above the Biotechnology industry median of 183.88. Gyre Therapeutics' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current Days Inventory is 800.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (GYRE) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of $6.50 is trading 33.8% below its estimated GF Value™ of $9.82.
GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.
Key valuation signals for GYRE:
Days Inventory: 800.32 (60% above median its 10-year median of 498.91)
GF Value™: $9.82 vs. price of $6.50 (33.8% below fair value)
Industry Position: 335.3% above the Biotechnology median (#537 of 638)
No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score
Get the complete analysis for GYRE
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GYRE has been successfully added to your 
